key: cord-0806823-yz1mlbj1 authors: Amaral, Lucas Tadashi Wada; Fonseca, Eduardo Kaiser Ururahy Nunes; Jacomelli, Márcia; Szarf, Gilberto; Chate, Rodrigo Caruso title: Hemophagocytic syndrome: a potential COVID-19 complication date: 2020 journal: J Bras Pneumol DOI: 10.36416/1806-3756/e20200296 sha: d59fb436cc472e5ae27c16561e32ceca9751f8da doc_id: 806823 cord_uid: yz1mlbj1 nan A 62-year-old male smoker who was an alcoholic and had diabetes was being treated for mediastinitis after surgical myocardial revascularization when he presented with worsening of the respiratory pattern despite overall improvement, requiring endotracheal intubation. The patient underwent a CT scan of the chest that showed findings consistent with COVID-19 ( Figures 1A and 1B) , which was later confirmed by RT-PCR. Seventeen days after the diagnosis of COVID-19, the patient presented with pancytopenia and increased levels of ferritin and IL-2 receptor. Hemophagocytic syndrome (HPS) was therefore suspected. A myelogram confirmed the diagnosis of HPS. Treatment consisted of i.v. immunoglobulin for two days. Thirteen days after the diagnosis of HPS, the patient experienced decreased oxygen saturation and tachypnea. A new CT scan of the chest showed new cavitating pulmonary lesions, superimposed on the pulmonary findings of COVID-19 ( Figures 1C and 1D ). Bronchoscopy revealed grossly necrotic tissue and bronchial infection with Aspergillus fumigatus ( Figure 1E ). The patient was started on anidulafungin in an attempt to contain the fungal infection; however, given the severity of his condition, he died three days after treatment initiation. HPS is a rare and severe complication characterized by fever, hepatosplenomegaly, cytopenia, and activated macrophages in hematopoietic organs. It is often related to infectious diseases, and it can increase the risk of developing opportunistic infections. (1) New evidence indicates that HPS can occur in the context of COVID-19, (2, 3) carrying an ominous prognosis. A Hemophagocytic Lymphohistiocytosis Case with Newly Defined UNC13D (c.175G>C; p.Ala59Pro) Mutation and a Rare Complication Cytokine release syndrome in severe COVID-19 Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19 e20200296 IMAGES IN PULMONARY MEDICINE